---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-055402"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:10:17.303412+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings: Phase 3 Trappsol Cyclo NPC1 study continues after DMC interim review

## Summary
- DMC recommends continuation of 96-week TransportNPC study after 48-week interim safety/efficacy analysis.
- Trappsol Cyclo well-tolerated; safety profile consistent with prior Phase 1/2 and open-label studies.
- FDA accepted statistical analysis plan for the TransportNPC study.
- Rafael closed $25M rights offering earlier June to support strategic objectives, including NPC program.
- Study is described as most comprehensive controlled pivotal study for NPC in patient size and global footprint.

## SEC filing metadata
- accession: 0001213900-25-055402
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390025055402/0001213900-25-055402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390025055402/ea0246139-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-055402
- JSON: https://secwatch.observer/filing/0001213900-25-055402.json
- Plain text: https://secwatch.observer/filing/0001213900-25-055402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.